Wnt4 signaling prevents skeletal aging and inflammation by inhibiting nuclear factor-κB

Nature Medicine

Volumn 20, Issue 9, 2014, Pages 1009-1017

  Yu, Bo ^a   Chang, Jia ^a   Liu, Yunsong ^b   Li, Jiong ^a   Kevork, Kareena ^a   Al Hezaimi, Khalid ^c   Graves, Dana T ^d   Park, No Hee ^a,e   Wang, Cun Yu ^a,f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b PEKING UNIVERSITY SCHOOL AND HOSPITAL OF STOMATOLOGY   (China)

^c KING SAUD UNIVERSITY   (Saudi Arabia)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f University of California   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TUMOR NECROSIS FACTOR ALPHA; WNT4 PROTEIN; WNT4 PROTEIN, MOUSE;

ANIMAL; ARTICLE; BONE; C57BL MOUSE; INFLAMMATION; METABOLISM; MOUSE; OSTEOPOROSIS; OVARIECTOMY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; BONE AND BONES; ESTROGENS; INFLAMMATION; MICE; MICE, INBRED C57BL; NF-KAPPA B; OSTEOPOROSIS; OVARIECTOMY; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA; WNT4 PROTEIN;

EID: 84908313333     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.3586     Document Type: Article

References (62)

1. Manolagas, S. C. , Jilka, R. L. Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N. Engl. J. Med. 332, 305-311 (1995).
2. Zaidi, M. Skeletal remodeling in health and disease. Nat. Med. 13, 791-801 (2007).
3. Manolagas, S. C. , Parfitt, A. M. What old means to bone. Trends Endocrinol. Metab. 21, 369-374 (2010).
4. Chien, K. R. , Karsenty, G. Longevity and lineages: toward the integrative biology of degenerative diseases in heart, muscle, and bone. Cell 120, 533-544 (2005).
5. Bruunsgaard, H. et al. Predicting death from tumour necrosis factor-α and interleukin-6 in 80-year-old people. Clin. Exp. Immunol. 132, 24-31 (2003).
6. Weitzmann, M. N. , Pacifici, R. Estrogen deficiency and bone loss: an inflammatory tale. J. Clin. Invest. 116, 1186-1194 (2006).
7. McLean, R. R. Proinflammatory cytokines and osteoporosis. Curr. Osteoporos. Rep. 7, 134-139 (2009).
8. López-Otín, C. , Blasco, M. A. , Partridge, L. , Serrano, M. , Kroemer, G. The hallmarks of aging. Cell 153, 1194-1217 (2013).
9. Teitelbaum, S. L. Bone resorption by osteoclasts. Science 289, 1504-1508 (2000).
10. Wagner, E. F. , Karsenty, G. Genetic control of skeletal development. Curr. Opin. Genet. Dev. 11, 527-532 (2001).
11. Raisz, L. G. Pathogenesis of osteoporosis: concepts, conflicts, and prospects. J. Clin. Invest. 115, 3318-3325 (2005).
12. Riggs, B. L. , Khosla, S. , Melton, L. J. III. A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J. Bone Miner. Res. 13, 763-773 (1998).
13. Khosla, S. , Riggs, B. L. Pathophysiology of age-related bone loss and osteoporosis. Endocrinol. Metab. Clin. North Am. 34, 1015-1030 (2005).
14. Sun, L. et al. FSH directly regulates bone mass. Cell 125, 247-260 (2006).
15. Ghosh, S. , Karin, M. Missing pieces in the NF-κB puzzle. Cell 109, S81-S96 (2002).
16. Boyce, B. F. , Yao, Z. , Xing, L. Functions of nuclear factor, kappa;B in bone. Ann. NY Acad. Sci. 1192, 367-375 (2010).
17. Jimi, E. , Ghosh, S. Role of nuclear factor-κB in the immune system and bone. Immunol. Rev. 208, 80-87 (2005).
18. Krum, S. A. , Chang, J. , Miranda-Carboni, G. , Wang, C. Y. Novel functions for NF-κB: inhibition of bone formation. Nat. Rev. Rheumatol. 6, 607-611 (2010).
19. Almeida, M. , Han, L. , Ambrogini, E. , Bartell, S. M. , Manolagas, S. C. Oxidative stress stimulates apoptosis and activates NF-κB in osteoblastic cells via a PKCβ/p66shc signaling cascade: counter regulation by estrogens or androgens. Mol. Endocrinol. 24, 2030-2037 (2010).
20. Jimi, E. et al. Selective inhibition of NF-κB blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo. Nat. Med. 10, 617-624 (2004).
21. Chen, Q. et al. DNA damage drives accelerated bone aging via an NF-κB-dependent mechanism. J. Bone Miner. Res. 28, 1214-1228 (2013).
22. Chang, J. et al. Inhibition of osteoblastic bone formation by nuclear factor-κB. Nat. Med. 15, 682-689 (2009).
23. Anastas, J. N. , Moon, R. T. WNT signalling pathways as therapeutic targets in cancer. Nat. Rev. Cancer 13, 11-26 (2013).
24. MacDonald, B. T. , Tamai, K. , He, X. Wnt/β-catenin signaling: components, mechanisms, and diseases. Dev. Cell 17, 9-26 (2009).
25. Regard, J. B. , Zhong, Z. , Williams, B. O. , Yang, Y. Wnt signaling in bone development and disease: making stronger bone with Wnts. Cold Spring Harb. Perspect. Biol. 4, 1-12 (2012).
26. Baron, R. , Kneissel, M. WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat. Med. 19, 179-192 (2013).
27. Veeman, M. T. , Axelrod, J. D. , Moon, R. T. A second canon. Functions and mechanisms of, beta;-catenin-independent Wnt signaling. Dev. Cell 5, 367-377 (2003).
28. Seifert, J. R. , Mlodzik, M. Frizzled/PCP signalling: a conserved mechanism regulating cell polarity and directed motility. Nat. Rev. Genet. 8, 126-138 (2007).
29. McNeill, H. , Woodgett, J. R. When pathways collide: collaboration and connivance among signalling proteins in development. Nat. Rev. Mol. Cell Biol. 11, 404-413 (2010).
30. Lako, M. et al. Isolation, characterisation and embryonic expression of WNT11, a gene which maps to 11q13. 5 and has possible roles in the development of skeleton, kidney and lung. Gene 219, 101-110 (1998).
31. Qiu, W. , Chen, L. , Kassem, M. Activation of non-canonical Wnt/JNK pathway by Wnt3a is associated with differentiation fate determination of human bone marrow stromal (mesenchymal) stem cells. Biochem. Biophys. Res. Commun. 413, 98-104 (2011).
32. Maeda, K. et al. Wnt5a-Ror2 signaling between osteoblast-lineage cells and osteoclast precursors enhances osteoclastogenesis. Nat. Med. 18, 405-412 (2012).
33. Chang, J. et al. Noncanonical Wnt-4 signaling enhances bone regeneration of mesenchymal stem cells in craniofacial defects through activation of p38 MAPK. J. Biol. Chem. 282, 30938-30948 (2007).
34. Krebsbach, P. H. et al. Transgenic expression of COL1A1-chloramphenicol acetyltransferase fusion genes in bone: differential utilization of promoter elements in vivo and in cultured cells. Mol. Cell. Biol. 13, 5168-5174 (1993).
35. Liu, F. et al. Expression and activity of osteoblast-targeted Cre recombinase transgenes in murine skeletal tissues. Int. J. Dev. Biol. 48, 645-653 (2004).
36. Khosla, S. , Westendorf, J. J. , Oursler, M. J. Building bone to reverse osteoporosis and repair fractures. J. Clin. Invest. 118, 421-428 (2008).
37. Halleen, J. M. et al. Tartrate-resistant acid phosphatase 5b: a novel serum marker of bone resorption. J. Bone Miner. Res. 15, 1337-1345 (2000).
38. Pacifici, R. et al. Effect of surgical menopause and estrogen replacement on cytokine release from human blood mononuclear cells. Proc. Natl. Acad. Sci. USA 88, 5134-5138 (1991).
39. Jilka, R. L. et al. Increased osteoclast development after estrogen loss: mediation by interleukin-6. Science 257, 88-91 (1992).
40. Hayward, M. D. et al. An extensive phenotypic characterization of the hTNFα transgenic mice. BMC Physiol. 7, 13 (2007).
41. Guo, R. et al. Ubiquitin ligase Smurf1 mediates tumor necrosis factor-induced systemic bone loss by promoting proteasomal degradation of bone morphogenetic signaling proteins. J. Biol. Chem. 283, 23084-23092 (2008).
42. Yao, Z. , Xing, L. , Boyce, B. F. NF-κB p100 limits TNF-induced bone resorption in mice by a TRAF3-dependent mechanism. J. Clin. Invest. 119, 3024-3034 (2009).
43. Lam, J. et al. TNF-α induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J. Clin. Invest. 106, 1481-1488 (2000).
44. Pandey, A. C. et al. MicroRNA profiling reveals age-dependent differential expression of nuclear factor, kappa;B and mitogen-activated protein kinase in adipose and bone marrow-derived human mesenchymal stem cells. Stem Cell Res. Ther. 2, 49 (2011).
45. Garnero, P. , Sornay-Rendu, E. , Chapuy, M. C. , Delmas, P. D. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J. Bone Miner. Res. 11, 337-349 (1996).
46. Ginaldi, L. , Di Benedetto, M. C. , De Martinis, M. Osteoporosis, inflammation and ageing. Immun. Ageing 2, 14 (2005).
47. Lomaga, M. A. et al. TRAF6 deficiency results in osteopetrosisa and defective interleukin-1, CD40, and LPS signaling. Genes Dev. 13, 1015-1024 (1999).
48. Bai, S. , Zha, J. , Zhao, H. , Ross, F. P. , Teitelbaum, S. L. Tumor necrosis factor receptor-associated factor 6 is an intranuclear transcriptional coactivator in osteoclasts. J. Biol. Chem. 283, 30861-30867 (2008).
49. Mizukami, J. et al. Receptor activator of NF-κB ligand (RANKL) activates TAK1 mitogen-activated protein kinase kinase kinase through a signaling complex containing RANK, TAB2, and TRAF6. Mol. Cell. Biol. 22, 992-1000 (2002).
50. Takada, I. et al. A histone lysine methyltransferase activated by non-canonical Wnt signalling suppresses PPAR-γ transactivation. Nat. Cell Biol. 9, 1273-1285 (2007).
51. Teitelbaum, S. L. , Ross, F. P. Genetic regulation of osteoclast development and function. Nat. Rev. Genet. 4, 638-649 (2003).
52. Asagiri, M. et al. Autoamplification of NFATc1 expression determines its essential role in bone homeostasis. J. Exp. Med. 202, 1261-1269 (2005).
53. Holmen, S. L. et al. Essential role of, beta;-catenin in postnatal bone acquisition. J. Biol. Chem. 280, 21162-21168 (2005).
54. Lories, R. J. , Corr, M. , Lane, N. E. To Wnt or not to Wnt: the bone and joint health dilemma. Nat. Rev. Rheumatol. 9, 328-339 (2013).
55. Winkel, A. et al. Wnt-ligand-dependent interaction of TAK1 (TGF-β-activated kinase-1) with the receptor tyrosine kinase Ror2 modulates canonical Wnt-signalling. Cell. Signal. 20, 2134-2144 (2008).
56. Li, M. et al. TAB2 scaffolds TAK1 and NLK in repressing canonical Wnt signaling. J. Biol. Chem. 285, 13397-13404 (2010).
57. Sugimura, R. et al. Noncanonical Wnt signaling maintains hematopoietic stem cells in the niche. Cell 150, 351-365 (2012).
58. Heinonen, K. M. , Vanegas, J. R. , Lew, D. , Krosl, J. , Perreault, C. Wnt4 enhances murine hematopoietic progenitor cell expansion through a planar cell polarity-like pathway. PLoS ONE 6, e19279 (2011).
59. Fan, Z. et al. BCOR regulates mesenchymal stem cell function by epigenetic mechanisms. Nat. Cell Biol. 11, 1002-1009 (2009).
60. Redlich, K. et al. Osteoclasts are essential for TNF-α-mediated joint destruction. J. Clin. Invest. 110, 1419-1427 (2002).
61. Thwin, M. M. et al. Effect of phospholipase A2 inhibitory peptide on inflammatory arthritis in a TNF transgenic mouse model: a time-course ultrastructural study. Arthritis Res. Ther. 6, R282-R294 (2004).
62. Li, J. et al. LATS2 suppresses oncogenic Wnt signaling by disrupting, beta;-catenin/BCL9 interaction. Cell Rep. 5, 1650-1663 (2013).